Loading...

Alexion Pharmaceuticals

DB:AXP
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AXP
DB
$28B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
AXP Share Price and Events
7 Day Returns
-3.4%
DB:AXP
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
32.1%
DB:AXP
-7.9%
DE Biotechs
-7.2%
DE Market
AXP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alexion Pharmaceuticals (AXP) -3.4% 2.3% 24.3% 32.1% -11% 7.3%
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • AXP outperformed the Biotechs industry which returned -7.9% over the past year.
  • AXP outperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
AXP
Industry
5yr Volatility vs Market
Related Companies

AXP Value

 Is Alexion Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Alexion Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Alexion Pharmaceuticals.

DB:AXP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AXP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (11.42%))
1.394
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.394 * 5.96%)
8.53%

Discounted Cash Flow Calculation for DB:AXP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Alexion Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:AXP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.53%)
2019 1,845.68 Analyst x6 1,700.57
2020 2,295.35 Analyst x6 1,948.60
2021 2,877.00 Analyst x3 2,250.35
2022 3,357.60 Analyst x2 2,419.78
2023 3,559.05 Analyst x2 2,363.29
2024 3,706.70 Est @ 4.15% 2,267.82
2025 3,816.88 Est @ 2.97% 2,151.62
2026 3,898.91 Est @ 2.15% 2,025.05
2027 3,960.23 Est @ 1.57% 1,895.18
2028 4,006.54 Est @ 1.17% 1,766.59
Present value of next 10 years cash flows $20,788.85
DB:AXP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $4,006.54 × (1 + 0.23%) ÷ (8.53% – 0.23%)
$48,350.29
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $48,350.29 ÷ (1 + 8.53%)10
$21,318.94
DB:AXP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $20,788.85 + $21,318.94
$42,107.79
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $42,107.79 / 224.30
$187.73
DB:AXP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AXP represents 0.95624x of NasdaqGS:ALXN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.95624x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 187.73 x 0.95624
€179.52
Value per share (EUR) From above. €179.52
Current discount Discount to share price of €120.40
= -1 x (€120.40 - €179.52) / €179.52
32.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Alexion Pharmaceuticals is available for.
Intrinsic value
33%
Share price is €120.4 vs Future cash flow value of €179.52
Current Discount Checks
For Alexion Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Alexion Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Alexion Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alexion Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alexion Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AXP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.35
NasdaqGS:ALXN Share Price ** NasdaqGS (2019-04-17) in USD $125.91
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alexion Pharmaceuticals.

DB:AXP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ALXN Share Price ÷ EPS (both in USD)

= 125.91 ÷ 0.35

361.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alexion Pharmaceuticals is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Alexion Pharmaceuticals is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Alexion Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:AXP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 361.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
26.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:AXP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 361.34x ÷ 26.4%

13.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alexion Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Alexion Pharmaceuticals's assets?
Raw Data
DB:AXP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $41.01
NasdaqGS:ALXN Share Price * NasdaqGS (2019-04-17) in USD $125.91
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:AXP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ALXN Share Price ÷ Book Value per Share (both in USD)

= 125.91 ÷ 41.01

3.07x

* Primary Listing of Alexion Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alexion Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Alexion Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alexion Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AXP Future Performance

 How is Alexion Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alexion Pharmaceuticals expected to grow at an attractive rate?
  • Alexion Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Alexion Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Alexion Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AXP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AXP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 26.4%
DB:AXP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 10.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AXP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AXP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 7,092 3,294 3,284 7
2022-12-31 6,576 3,042 2,689 10
2021-12-31 5,979 2,765 2,305 14
2020-12-31 5,434 2,477 1,969 17
2019-12-31 4,759 1,995 1,617 17
DB:AXP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 4,131 426 78
2018-09-30 3,912 601 153
2018-06-30 3,745 483 -100
2018-03-31 3,612 1,107 522
2017-12-31 3,551 1,116 443
2017-09-30 3,473 1,241 507
2017-06-30 3,412 1,261 523
2017-03-31 3,253 1,220 478
2016-12-31 3,084 1,086 399
2016-09-30 2,954 894 372
2016-06-30 2,821 827 94
2016-03-31 2,705 826 145

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alexion Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Alexion Pharmaceuticals's revenue is expected to grow by 10.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AXP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Alexion Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AXP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 14.94 16.47 13.49 4.00
2022-12-31 12.11 14.31 8.29 6.00
2021-12-31 10.34 12.99 7.45 6.00
2020-12-31 8.72 10.09 6.95 8.00
2019-12-31 7.18 8.45 6.65 9.00
DB:AXP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.35
2018-09-30 0.69
2018-06-30 -0.45
2018-03-31 2.34
2017-12-31 1.98
2017-09-30 2.26
2017-06-30 2.33
2017-03-31 2.13
2016-12-31 1.78
2016-09-30 1.66
2016-06-30 0.42
2016-03-31 0.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Alexion Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Alexion Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alexion Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AXP Past Performance

  How has Alexion Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alexion Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alexion Pharmaceuticals's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Alexion Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Alexion Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
Alexion Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alexion Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AXP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4,131.20 77.60 1,092.40 730.30
2018-09-30 3,912.10 152.60 1,067.00 774.40
2018-06-30 3,744.70 -100.30 1,080.40 794.30
2018-03-31 3,612.40 522.30 1,075.20 819.10
2017-12-31 3,551.10 443.30 1,083.50 862.10
2017-09-30 3,472.50 506.70 1,049.60 818.60
2017-06-30 3,412.40 522.70 1,015.40 818.90
2017-03-31 3,252.70 477.50 981.80 800.70
2016-12-31 3,084.10 399.40 953.00 757.20
2016-09-30 2,953.82 372.22 906.98 741.56
2016-06-30 2,821.46 94.46 889.50 712.23
2016-03-31 2,704.67 144.68 878.88 663.92
2015-12-31 2,604.00 144.40 862.60 709.50
2015-09-30 2,502.66 231.11 804.80 647.55
2015-06-30 2,391.17 592.60 749.94 582.54
2015-03-31 2,267.45 588.88 688.03 543.41
2014-12-31 2,234.00 657.00 630.00 514.00
2014-09-30 2,076.17 484.59 581.25 470.46
2014-06-30 1,921.43 400.64 546.47 458.01
2014-03-31 1,779.02 330.03 510.19 434.01
2013-12-31 1,551.35 252.90 489.72 317.09
2013-09-30 1,429.96 352.86 467.53 294.72
2013-06-30 1,323.69 351.25 434.60 260.79
2013-03-31 1,228.32 291.63 406.26 251.86
2012-12-31 1,134.11 254.82 384.68 222.73
2012-09-30 1,041.15 222.02 358.62 193.72
2012-06-30 951.06 195.41 346.24 176.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Alexion Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Alexion Pharmaceuticals used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Alexion Pharmaceuticals has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Alexion Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alexion Pharmaceuticals has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AXP Health

 How is Alexion Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alexion Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alexion Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alexion Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Alexion Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alexion Pharmaceuticals Company Filings, last reported 3 months ago.

DB:AXP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 9,165.30 3,224.60 1,583.90
2018-09-30 9,169.70 3,205.70 1,557.70
2018-06-30 8,767.40 3,204.80 1,186.10
2018-03-31 9,112.70 3,196.50 1,606.50
2017-12-31 8,893.10 3,231.00 1,483.40
2017-09-30 8,944.00 3,265.00 1,533.00
2017-06-30 8,875.00 3,251.00 1,447.00
2017-03-31 8,856.00 3,283.00 1,464.00
2016-12-31 8,693.80 3,289.00 1,293.80
2016-09-30 8,504.10 3,478.51 1,313.10
2016-06-30 8,199.34 3,452.49 1,180.05
2016-03-31 8,062.28 3,421.10 1,027.55
2015-12-31 8,259.00 3,571.00 1,385.00
2015-09-30 8,252.87 3,649.60 1,458.49
2015-06-30 8,552.87 3,629.56 1,494.35
2015-03-31 3,516.90 160.41 1,925.09
2014-12-31 3,302.02 164.60 1,961.57
2014-09-30 3,123.04 156.53 1,781.71
2014-06-30 2,881.58 141.02 1,594.36
2014-03-31 2,700.98 131.92 1,557.48
2013-12-31 2,382.08 145.23 1,514.85
2013-09-30 2,354.77 137.25 1,302.76
2013-06-30 2,211.54 143.85 1,119.39
2013-03-31 2,090.05 149.00 1,022.96
2012-12-31 1,970.85 149.00 989.50
2012-09-30 1,872.44 161.00 905.53
2012-06-30 1,749.69 228.00 806.21
  • Alexion Pharmaceuticals's level of debt (35.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (6.1% vs 35.2% today).
  • Debt is not well covered by operating cash flow (13.2%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 49.2x coverage).
X
Financial health checks
We assess Alexion Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alexion Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AXP Dividends

 What is Alexion Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alexion Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Alexion Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alexion Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alexion Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AXP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AXP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 4.00
2019-12-31 0.00 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alexion Pharmaceuticals has not reported any payouts.
  • Unable to verify if Alexion Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alexion Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alexion Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Alexion Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Alexion Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alexion Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alexion Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AXP Management

 What is the CEO of Alexion Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ludwig Hantson
COMPENSATION $16,490,250
AGE 55
TENURE AS CEO 2.1 years
CEO Bio

Dr. Ludwig N. Hantson, Ph.D., has been Chief Executive Officer at Alexion Pharmaceuticals, Inc. since March 27, 2017. Dr. Hantson has been the President of Synovis Life Technologies Inc. since February 14, 2012. Dr. Hantson served as the Chief Executive Officer at Baxalta Incorporated and also served as its President. Prior to Baxalta’s separation from Baxter in July 2015, he served as Corporate Vice President and President of Baxter BioScience Inc., having served in that capacity since October 2010. He joined Baxter in May 2010 as Corporate Vice President and President of International. From 2001 to May 2010, he held various positions at Novartis Pharmaceuticals Corporation. He served as the President of International at Baxter Healthcare Pty. Ltd. since May 2010. He served as the President of Bioscience Business at Baxter Internation, Inc. and President of International from May 3, 2010 to October 2010. He served as the Unit President and Corporate Vice President at Baxter International Inc. from May 3, 2010 to July 1, 2015 and also served as its President of BioScience from October 2010 to July 1, 2015. He served as the Chief Executive Officer of US at Novartis Pharmaceuticals Corporation since April 2008 and served as its Senior Vice President of Commercial Development and Specialty Businesses since December 2006. He oversaw New Product Commercialization, Business Development & Licensing and Mature Products and US Medical. He oversaw the franchises for IDTI (Infectious Diseases, Transplant & Immunology) and Ophthalmics. He joined Novartis AG in 2001 and served as its Head of Global Early Commercial Development and later served as the Head of the Global Neuroscience Business Franchise. He has more than 30 years of experience in the life sciences industry. He served as the Chief Executive Officer of North American Pharmaceuticals at Novartis AG until April 2010 and also served as its Head of North American Pharmaceuticals from April 2008 to April 2010. He served as the Chief Executive of US at Novartis Corporation since April 2008. He served as Chief Executive Officer of Novartis Europe. Before leading Region Europe, he served as the Head of Novartis Pharmaceuticals Canada, Inc., where he drove strong growth, increased market share and led Novartis Pharma Canada to be named one of the Best Employers in Canada. He served as President of Novartis Pharma Canada. Prior to joining Novartis, he spent 13 years at Johnson & Johnson (Janssen Pharmaceutica) in roles of increasing responsibility in the research and marketing areas. He began his career at Smith & Nephew and subsequently served in increasing roles of responsibility in marketing and research and development at Johnson & Johnson from 1988 to 2001. He has been a Director of Synovis Life Technologies Inc., since February 14, 2012. He has been a Director of Hologic, Inc. since November 19, 2018. He has been Director at Alexion Pharmaceuticals, Inc. since March 27, 2017. He serves as a Director of Canada’s Research-Based Pharmaceutical Companies. He served as a Director of Baxalta Incorporated until June 3, 2016. Dr. Hantson received his Ph.D. in Motor Rehabilitation and Physical Therapy from the University of Louvain, Belgium. He received Master’s degree in physical education and a certification in high secondary education, all from the University of Louvain in Belgium.

CEO Compensation
  • Ludwig's compensation has been consistent with company performance over the past year.
  • Ludwig's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alexion Pharmaceuticals management team in years:

1.8
Average Tenure
55
Average Age
  • The average tenure for the Alexion Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Ludwig Hantson

TITLE
CEO & Director
COMPENSATION
$16M
AGE
55
TENURE
2.1 yrs

Paul Clancy

TITLE
Executive VP & CFO
COMPENSATION
$5M
AGE
56
TENURE
1.8 yrs

Anne-Marie Law

TITLE
Executive VP and Chief Patient & Employee Experience Officer
COMPENSATION
$5M
AGE
51
TENURE
1.8 yrs

Brian Goff

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$5M
AGE
49
TENURE
1.8 yrs

John Orloff

TITLE
Executive VP and Head of Research & Development
COMPENSATION
$5M
AGE
61
TENURE
1.8 yrs

Daniel Bazarko

TITLE
Chief Accounting Officer & Senior VP

Susan Altschuller

TITLE
Vice President of Investor Relations

Indrani M. Franchini

TITLE
Executive VP & Chief Compliance Officer
AGE
46
TENURE
1.8 yrs

Ellen Chiniara

TITLE
Executive VP
AGE
59
TENURE
1.2 yrs

Stephanie Oey

TITLE
Senior Vice President of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Alexion Pharmaceuticals board of directors in years:

2
Average Tenure
61.5
Average Age
  • The average tenure for the Alexion Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Brennan

TITLE
Independent Chairman of the Board
COMPENSATION
$449K
AGE
64
TENURE
1.9 yrs

Ludwig Hantson

TITLE
CEO & Director
COMPENSATION
$16M
AGE
55
TENURE
2.1 yrs

Jack Mollen

TITLE
Director
COMPENSATION
$374K
AGE
67
TENURE
5 yrs

Chris Coughlin

TITLE
Director
COMPENSATION
$534K
AGE
66
TENURE
4.8 yrs

Felix Baker

TITLE
Director
COMPENSATION
$374K
AGE
49
TENURE
3.8 yrs

Judy Reinsdorf

TITLE
Director
COMPENSATION
$595K
AGE
54
TENURE
1.2 yrs

Andreas Rummelt

TITLE
Director
COMPENSATION
$349K
AGE
62
TENURE
9.2 yrs

Paul Friedman

TITLE
Director
COMPENSATION
$349K
AGE
75
TENURE
1.6 yrs

Francois Nader

TITLE
Director
COMPENSATION
$349K
AGE
61
TENURE
1.4 yrs

Deborah Dunsire

TITLE
Independent Director
COMPENSATION
$583K
AGE
56
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • Alexion Pharmaceuticals insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Feb 19 Sell Daniel Bazarko Individual 14. Feb 19 14. Feb 19 -2,000 €111.75 €-223,499
03. Jan 19 Sell Ludwig Hantson Individual 31. Dec 18 31. Dec 18 -3,244 €83.72 €-271,573
30. Nov 18 Sell Indrani M. Franchini Individual 28. Nov 18 28. Nov 18 -2,605 €104.70 €-272,740
12. Jul 18 Sell Paul Clancy Individual 10. Jul 18 10. Jul 18 -5,241 €111.78 €-585,862
12. Jun 18 Sell Indrani M. Franchini Individual 08. Jun 18 08. Jun 18 -1,466 €100.79 €-147,752
12. Jun 18 Sell Brian Goff Individual 08. Jun 18 08. Jun 18 -1,645 €100.79 €-165,793
12. Jun 18 Sell Anne-Marie Law Individual 08. Jun 18 08. Jun 18 -1,862 €100.79 €-187,664
12. Jun 18 Sell John Orloff Individual 08. Jun 18 08. Jun 18 -2,115 €100.79 €-213,163
02. May 18 Buy Christopher Coughlin Individual 30. Apr 18 30. Apr 18 10,000 €100.04 €1,000,383
X
Management checks
We assess Alexion Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alexion Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AXP News

Simply Wall St News

AXP Company Info

Description

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Details
Name: Alexion Pharmaceuticals, Inc.
AXP
Exchange: DB
Founded: 1992
$24,991,003,344
224,300,000
Website: http://www.alexion.com
Address: Alexion Pharmaceuticals, Inc.
121 Seaport Boulevard,
Boston,
Massachusetts, 02210,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ALXN Common Stock Nasdaq Global Select US USD 28. Feb 1996
DB AXP Common Stock Deutsche Boerse AG DE EUR 28. Feb 1996
XTRA AXP Common Stock XETRA Trading Platform DE EUR 28. Feb 1996
LSE 0QZM Common Stock London Stock Exchange GB USD 28. Feb 1996
WBAG ALXN Common Stock Wiener Boerse AG AT EUR 28. Feb 1996
BMV ALXN * Common Stock Bolsa Mexicana de Valores MX MXN 28. Feb 1996
Number of employees
Current staff
Staff numbers
2,656
Alexion Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 22:19
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/02/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.